Cyclerion Therapeutics, Inc. (CYCN)
Company Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases.
Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.
It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders.
It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms.
The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Country | United States |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 1 |
CEO | Dr. Regina Graul Ph.D. |
Contact Details
Address: 301 Binney Street Cambridge, Massachusetts 02142 United States | |
Phone | 617-621-7722 |
Website | cyclerion.com |
Stock Details
Ticker Symbol | CYCN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001755237 |
CUSIP Number | 23255M105 |
ISIN Number | US23255M2044 |
Employer ID | 83-1895370 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Regina Graul Ph.D. | President |
Rhonda M. Chicko | Chief Financial Officer |
Dr. Todd Milne Ph.D. | Senior Vice President of External Innovation |
Jessica Rennekamp | Associate Director of Corporate Communications |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 5, 2024 | 10-K | Annual Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Dec 5, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Dec 4, 2023 | 8-K | Current Report |
Dec 1, 2023 | 8-K | Current Report |
Nov 24, 2023 | 8-K | Current Report |
Nov 13, 2023 | 10-Q | Quarterly Report |